SHSE:688276 (China)
Â
Ordinary Shares - Class A
Â¥
40.45
(-1.75%)
May 8
Business Description
Changchun BCHT Biotechnology Co
ISIN : CNE100005XY6
Share Class Description:
SHSE:688276: Ordinary Shares - Class ACompare
Compare
Traded in other countries / regions
688276.China IPO Date
2021-06-25Description
Changchun BCHT Biotechnology Co is a biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.11 | |||||
| Interest Coverage | 73.21 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 11.53 | |||||
| Beneish M-Score | -1.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.9 | |||||
| 3-Year EBITDA Growth Rate | 1.9 | |||||
| 3-Year EPS without NRI Growth Rate | 1.8 | |||||
| 3-Year FCF Growth Rate | -14.7 | |||||
| 3-Year Book Growth Rate | 26.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.48 | |||||
| 9-Day RSI | 46.19 | |||||
| 14-Day RSI | 41.67 | |||||
| 6-1 Month Momentum % | -34.54 | |||||
| 12-1 Month Momentum % | -37.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.26 | |||||
| Quick Ratio | 2.03 | |||||
| Cash Ratio | 0.39 | |||||
| Days Inventory | 444.08 | |||||
| Days Sales Outstanding | 240.75 | |||||
| Days Payable | 51.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.36 | |||||
| Dividend Payout Ratio | 0.1 | |||||
| Forward Dividend Yield % | 0.36 | |||||
| 5-Year Yield-on-Cost % | 0.36 | |||||
| 3-Year Average Share Buyback Ratio | -3.6 | |||||
| Shareholder Yield % | 0.37 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.57 | |||||
| Operating Margin % | 35.32 | |||||
| Net Margin % | 28.36 | |||||
| FCF Margin % | -12.99 | |||||
| ROE % | 14.17 | |||||
| ROA % | 11.52 | |||||
| ROIC % | 17.73 | |||||
| ROC (Joel Greenblatt) % | 23.19 | |||||
| ROCE % | 15.96 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 30.64 | |||||
| PE Ratio without NRI | 26.93 | |||||
| Price-to-Owner-Earnings | 117.9 | |||||
| PEG Ratio | 2.24 | |||||
| PS Ratio | 8.5 | |||||
| PB Ratio | 4.1 | |||||
| Price-to-Tangible-Book | 4.47 | |||||
| Price-to-Operating-Cash-Flow | 63.8 | |||||
| EV-to-EBIT | 27.24 | |||||
| EV-to-EBITDA | 27.24 | |||||
| EV-to-Revenue | 8.72 | |||||
| EV-to-FCF | -66.93 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.81 | |||||
| Price-to-Graham-Number | 2.31 | |||||
| Price-to-Net-Current-Asset-Value | 13.35 | |||||
| Earnings Yield (Greenblatt) % | 3.67 | |||||
| FCF Yield % | -1.49 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers